Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4998178 | 0.81 | RXFP1 (0.67) | RXFP1MEN1KMT2ATP53ALDH1A1 | |
| SCHEMBL5002038 | 0.80 | RXFP1 (0.51) | RXFP1NPC1MAPTMEN1KMT2A | |
| SCHEMBL2326927 | 0.74 | MCL1 (0.57) | RXFP1MAPTGAAKDM4ESMN1; SMN2 | |
| SCHEMBL5005344 | 0.73 | SLC9A1 (0.51) | MAPTKDM4EKDM1ARCOR1SMN1; SMN2 | |
| SCHEMBL5008054 | 0.73 | KDM4E (0.47) | RXFP1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL11608138 | 0.71 | RXFP1 (0.60) | RXFP1NPC1MAPTMEN1GAA | |
| SCHEMBL10963185 | 0.71 | MEN1 (0.71) | NPC1MAPTMEN1GAAKMT2A | |
| SCHEMBL10428048 | 0.71 | P2RX1 (0.57) | NPC1MAPTMEN1GAAKMT2A | |
| SCHEMBL5981594 | 0.70 | MAPT (0.58) | RXFP1NPC1MAPTMEN1KMT2A | |
| SCHEMBL19332243 | 0.70 | PHGDH (0.69) | RXFP1MAPTTP53THRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064143-B1 | Positive modulators of nicotinic receptor agonists | ASTRAZENECA AB (SE) | 2006-06-20 | — | — | US | claimed |
| EP-1230218-A1 | POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS | AstraZeneca AB (SE) | 2002-08-14 | — | — | EP | claimed |
| WO-2001032622-A1 | POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | claimed |
| US-7402604-B2 | Positive modulators of nicotinic receptor agonists | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7064143-B1 | Positive modulators of nicotinic receptor agonists | ASTRAZENECA AB (SE) | 2006-06-20 | — | — | US | disclosed |
| US-20050245595-A1 | Positive modulators of nicotinic receptor agonists | GURLEY DAVID | 2005-11-03 | — | — | US | disclosed |
| EP-1230218-A1 | POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS | AstraZeneca AB (SE) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001032622-A1 | POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245595-A1 | Positive modulators of nicotinic receptor agonists | CHRM1, CHRM2, CHRNA1 | RXFP1 107/4885NPC1 1396/4885MAPT 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.